Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

News In Brief

This article was originally published in The Gray Sheet

  • News

Executive Summary

Illumina rejects Roche’s increased bid. Medtronic settles shareholder suit over Infuse. HeartWare buys WorldHeart for $8 million. More news briefs.

You may also be interested in...



News In Brief

CryoLife buys Hemosphere. Medtronic Infuse case closed. More news briefs.

News In Brief

CMS pushes back sunshine data collection date. Conceptus and Hologic settle contraception patent dispute. More news briefs.

Senate Aging Committee To Step Up Oversight On Sunshine Act

Committee Chairman Herb Kohl has drafted a letter asking CMS to adhere to a reasonable timeline in finalizing requirements for device makers to report payments to physicians and teaching hospitals.

Table

View full table

Related Content

Medtech Insight
Medtech Insight
Medtech Insight

Topics

Related Companies

Tags:
Medical Device
Latest Headlines

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

See All
UsernamePublicRestriction

Register

MT031122

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By